Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and JS004 Combined With Chemotherapy for Extensive-stage or Relapsed SCLC
NCT06648200Phase 2Completed
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tifcemalimab in small cell lung cancer (SCLC), sponsored by Shanghai Pulmonary Hospital. Started Nov 2024; status: completed.
02
Drugs
tifcemalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06648200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06648200.